• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Follow-up with serum cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
【24h】

Follow-up with serum cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.

机译：头颈部鳞状细胞癌患者的血清Cyfra 21-1随访。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Finding tumor markers for disease progression, and especially development of distant metastases, is desirable for patients with squamous cell carcinoma of the head and neck (SCCHN). Elevated serum levels of Cyfra 21-1 (cytokeratin fraction 21-1) have been frequently associated with disease progression in patients with lung cancer. In SCCHN, Cyfra 21-1 has not been established as a routine tumor marker yet, probably due to difficulties in finding the appropriate cut-off for the serum level. The aim of this study was to investigate whether assessment of changes in serum Cyfra 21-1 over time can predict distant metastases in patients with SCCHN, without attempting to establish an arbitrary cut-off for abnormal levels. Methods: Cyfra 21-1 serum levels of 25 patients with SCCHN and distant metastases were evaluated by means of an ELISA test kit. Results: There was a wide range of Cyfra 21-1 serum levels at the time of primary diagnosis, without correlation with tumor size, lymph node status, time to recurrence, or presence of distant metastases. All patients had a clear increase of Cyfra 21-1 levels which preceded the appearance of distant metastases clinically. Conclusions: Due to the wide range of Cyfra 21-1 levels at the time of primary tumor diagnosis, Cyfra-21-1 is neither a suitable screening marker for SCCHN, nor for diagnosis of distant metastases at the time of initial diagnosis of the tumor, but is of evident prognostic value for follow-up, especially for early detection of distant metastases. Copyright 2002 S. Karger AG, Basel
机译：目的：寻找疾病进展尤其是远处转移发生的肿瘤标志物，对于头颈部鳞状细胞癌（SCCHN）患者是理想的。 Cyfra 21-1（细胞角蛋白分数21-1）的血清水平升高经常与肺癌患者的疾病进展相关。在SCCHN中，尚未将Cyfra 21-1建立为常规的肿瘤标志物，可能是由于难以找到适合血清水平的临界值所致。这项研究的目的是调查评估血清Cyfra 21-1随时间变化的变化是否可以预测SCCHN患者的远处转移，而无需尝试为异常水平建立任意的临界值。方法：通过ELISA检测试剂盒评估25例SCCHN和远处转移患者的Cyfra 21-1血清水平。结果：初次诊断时存在广泛的Cyfra 21-1血清水平，与肿瘤大小，淋巴结状态，复发时间或远处转移无关。在临床上出现远处转移之前，所有患者的Cyfra 21-1水平均明显升高。结论：由于在原发肿瘤诊断时Cyfra 21-1的水平范围很广，Cyfra-21-1既不是SCCHN的合适筛选标志物，也不是初次诊断肿瘤时诊断远处转移的标志，但对随访具有明显的预后价值，特别是对于早期发现远处转移灶。版权所有2002 S. Karger AG，巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号